Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 31, 2013. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in the company's ordinary shares, filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding executive compensation vesting rather than a financial performance report.
Material Changes
The filing details a specific transaction involving Dr. P Vallance. Following the vesting on January 29, 2013, of 25% of an award made on January 29, 2007, under the GlaxoSmithKline Deferred Investment Award Plan, Dr. Vallance is scheduled to receive a cash payment. The payment rate is 1433.75p per share in respect of 4,997.121 notional Ordinary shares, payable on February 20, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Executive Compensation Event: Dr. P Vallance received a vesting notification for 25% of a 2007 Deferred Investment Award.
- Payment Details: A cash payment of 1433.75p per share on 4,997.121 notional shares is due on February 20, 2013.
- Regulatory Basis: The disclosure was made to comply with Disclosure and Transparency Rule 3.1.4R(1)(a).
- Financial Data Absence: No operational or financial performance metrics are included in this specific filing.